Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Mid Cap Fund median (32 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Taurus Mid Cap Fund |
|---|---|
| 03 Jan 2013 | ₹100.00 |
| 22 Feb 2014 | ₹93.26 |
| 13 Apr 2015 | ₹178.79 |
| 31 May 2016 | ₹166.26 |
| 20 Jul 2017 | ₹205.96 |
| 08 Sep 2018 | ₹236.19 |
| 28 Oct 2019 | ₹214.64 |
| 15 Dec 2020 | ₹276.61 |
| 03 Feb 2022 | ₹381.12 |
| 25 Mar 2023 | ₹369.15 |
| 13 May 2024 | ₹595.21 |
| 01 Jul 2025 | ₹653.45 |
| 20 Aug 2026 | ₹673.50 |
| Metric | Taurus · Direct · IDCW NAV ₹120.96 Very High risk ★★☆☆☆ | Category median Mid Cap Fund · 32 funds |
|---|---|---|
| +5.07% | +6.29% | |
| +12.16% | +14.78% | |
| +13.95% | +13.99% | |
| +13.29% | +9.73% | |
| +15.02% | +15.68% | |
| +12.89% | — | |
| +16.35% | +16.53% | |
| +15.66% | +14.94% | |
| +15.86% | +12.00% | |
| Risk | ||
| 18.39% | 16.93% | |
| 0.31 | 0.53 | |
| 0.40 | 0.73 | |
| -32.80% | -36.26% | |
| Nifty Midcap 150 | — | |
| -5.44% | -2.10% | |
| 0.97 | 0.97 | |
| 84.7% | 93.0% | |
| 105.5% | 95.9% | |
| 2.29% | 0.95% | |
| ₹121.80Cr | ₹7,889Cr | |
| — | — | |
| None | — | |
| ₹500 | — | |
| ₹500 | — | |
| 95% | 40% | |
| Anuj Kapil | — | |
| 03 Jan 2013 | — | |
| 37 | — | |
| 45.3% | — | |
| 3.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.